TAV Immunogenicity For HBV Infection Noninferior To MAV, Study Says

Infectious Disease Advisor (6/18, Aghjayan) reported, “Compared with a mono-antigenic vaccine (MAV), immunogenicity of a tri-antigenic vaccine (TAV) for hepatitis B virus (HBV) infection was found to be noninferior among adults 18 years of age and older a...